HK Stock Market Move | JINHAI MED TECH (02225) rose more than 5%, reaching a new high. Recently, it held discussions with China National Pharmaceutical Group to accelerate the commercialization process of high-end endoscopes.

JINHAI MED TECH (02225) rose more than 5%, reaching a high of 8.82 Hong Kong dollars, a new high since its listing. The stock price has increased by over 50% in the past month. As of the time of writing, it is up 5.5% at 8.82 Hong Kong dollars, with a trading volume of 6.658 million Hong Kong dollars. On the news front, recently JINHAI MED TECH has been in talks with Guoyao Ling merchants. The collaboration products of this talk mainly cover a basket of JINHAI MED TECH's leading products, including 4K3D fluorescence composite endoscopes, intervertebral foramen scopes, and a series of advanced instrument kits. The company stated that relying on Guoyao Ling's extensive channel advantages and strong market influence, JINHAI MED TECH's leading products can quickly cover a broader market and achieve rapid growth. It is worth noting that in recent years, JINHAI MED TECH has made significant breakthroughs in endoscope technology research and development. As of now, JINHAI MED TECH's 4K3D naked eye fluorescence endoscope camera system has obtained a Class II medical device license issued by the Shanghai Medical Products Administration, with multiple successful practical application cases. In addition, the company has recently received various honors, as JINHAI MED TECH's endoscope solution was recently selected as one of the "Top Ten National Medical Equipment Renewal Solutions" by China Good Doctor.